DG
Darwin Global Management, Ltd.
13F filer · CIK 0001839209Reported Aug 14, 2026
Net buyer this quarter
13F portfolio value$3.76BU.S. long equity reported on 13F
Positions50 new · 1 closed
Net flow last quarter+$491MBuys minus sells
Top 10 positions weight100.0%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 20265 positions | |||||
| $2.05B | 54.45% | 4.96% | +380.8% | Q1 2026 | |
| $674M | 17.91% | 2.95% | -61.7% | Q2 2024 | |
| $457M | 12.14% | 7.82% | +0.7% | Q4 2025 | |
| $348M | 9.26% | 4.61% | +4.4% | Q3 2025 | |
| $234M | 6.23% | 0.93% | -0.7% | Q1 2026 | |
| Q1 2026Reported May 15, 20266 positions | |||||
| $2.58B | 68.33% | 7.76% | -19.7% | Q2 2024 | |
| $456M | 12.10% | 7.77% | +1.0% | Q4 2025 | |
| $352M | 9.34% | 4.42% | +9.1% | Q3 2025 | |
| $205M | 5.44% | 1.10% | New | Q1 2026 | |
| $180M | 4.76% | 0.94% | New | Q1 2026 | |
| $1.46M | 0.04% | 0.03% | New | Q1 2026 | |
| Q4 2025Reported Feb 17, 20266 positions | |||||
| $3.64B | 73.78% | 9.77% | +2.3% | Q2 2024 | |
| $487M | 9.86% | 7.70% | New | Q4 2025 | |
| $440M | 8.90% | 4.05% | +0.4% | Q3 2025 | |
| CTCDTXCidara Therapeutics, Inc. | $220M | 4.46% | 3.17% | Not reported | Q2 2025 |
| $125M | 2.53% | 3.89% | New | Q4 2025 | |
| $23.2M | 0.47% | 1.39% | New | Q4 2025 | |
| Q3 2025Reported Nov 14, 20255 positions | |||||
| $2.9B | 80.54% | 9.62% | +5.8% | Q2 2024 | |
| $318M | 8.83% | 1.74% | New | Q3 2025 | |
| $264M | 7.33% | 5.00% | New | Q3 2025 | |
| CTCDTXCidara Therapeutics, Inc. | $95M | 2.64% | 3.40% | +29.8% | Q2 2025 |
| $23.8M | 0.66% | 0.64% | New | Q3 2025 | |
Premium opens every quarter this fund has filed